| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-16 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.34 | 4e-13 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.24 | 3e-07 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.16 | 1e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.17 | 8e-05 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |